The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

A phase II trial was conducted to determine the efficacy and toxicity of the addition of
interferon-[alpha] 2b (IFN-a [alpha]) to the chemotherapy combination of dacarbazine …

BACKGROUND The treatment of metastatic melanoma remains unsatisfactory despite
encouraging results with biotherapy and combination chemotherapy. Combining these two …

PURPOSE The goal of this study was to determine the therapeutic efficacy and toxicity of a
four-drug chemotherapy regimen combined with natural leukocyte interferon alfa (IFN-alpha) …

52 patients with metastatic melanoma have been treated with a combination of recombinant
interferon-alfa-2b, dacarbazine and nimustine. The objective response rate was 23% with 9 …

Background The treatment of metastatic melanoma remains unsatisfactory despite
encouraging results with biotherapy and combination chemotherapy. Combining these two …

The aim of this study was to evaluate the toxicity and efficacy of a monochemotherapy
regimen of dacarbazine (DTIC), tamoxifen, interferon-α2a and interleukin-2 (IL-2) and two …

Sixty-four patients with histologically confirmed metastatic malignant melanoma were
entered on a prospectively controlled randomized trial. Patients received dacarbazine …

PURPOSE To investigate the response rate, time to treatment failure (TTF), overall survival,
and toxicity in patients with metastatic melanoma treated with dacarbazine alone …

Background Based on phase II trial results, chemoimmunotherapy combinations have
become the preferred treatment for patients with metastatic melanoma in many institutions …